Physician profile
David E Odegaard
NPI 1023236213
$1,342.65
in general payments reported to CMS, 2019-2025
17 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $53.50 · 2021: $233 · 2022: $157 · 2023: $295 · 2024: $207 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.90 | 2021-2025 | Jardiance, Baqsimi |
| Bayer Healthcare Pharmaceuticals INC. | $211.97 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.97 | 2019-2025 | Jardiance |
| Abbvie INC. | $150.26 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $134.34 | 2020-2023 | |
| Abbott Laboratories | $92.46 | 2019-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $78.66 | 2019-2021 | |
| Amgen INC. | $53.32 | 2024-2025 | Tepezza |
| Medtronic, INC. | $33.94 | 2025 | Minimed 780g |
| Insulet Corporation | $26.20 | 2020 | |
| Esperion Therapeutics, INC. | $20.61 | 2025 | Nexletol |
| Pfizer INC. | $20.61 | 2025 | |
| Horizon Therapeutics Plc | $20.02 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $19.13 | 2024 | |
| Zealand Pharma US, INC. | $18.45 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $16.71 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Odegaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.